Clinical Trials & Studies
Opthea Coast – Actively Enrolling
A multicenter, randomized, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
Valo Health Spectra – Actively Enrolling
A Phase 2 randomized, double-masked, placebo controlled, multicenter study to evaluate the safety and efficacy of OPL-0401 oral pill in patients with non-proliferative diabetic retinopathy (NPDR).
Kodiak Sciences Inc GLOW – Enrollment Closed
A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW).
Sandoz Inc/Hexal AG Mylight – Enrollment Closed
A 52 week multicenter randomized, 2 arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 (biosimilar) to Eylea, administered intravitreally in patients with neovascular age related macular degeneration.
GSK – Enrollment Closed
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2798745 in Participants with Diabetic Macular Edema
Gyroscope Therapeutics – Enrollment Closed
The objective of this study is to evaluate subjects with geographic atrophy (GA) secondary to dry age related macular degeneration (AMD) by sequencing selected genes associated with AMD. Subjects who meet eligibility criteria will have the option to participapte in on-going or future Gyroscope Therapeutics sponsored studies.
Allergan Sequoia – Enrollment Closed
This is a phase 3 study for patients with treatment naive wet age related macular degeneration. This study is evaluating intravitreal abicipar (DARPin based anti-angiogenic drug), in comparison to intravitreal anti-VEGF ranibizmuab (Lucentis) injections. The estimated enrollment is 900 patients. The study started around June 2015, and will end around May 2019.
Yosemite – Enrollment Closed
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
Tenaya – Enrollment Closed
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Clearside Topaz - Enrollment Closed
A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-VEGF agent in subjects with retinal vein occlusion.
Novartis Merlin – Enrollment Closed
Study of Safety and Efficacy of Brolucizumab (Beovu) 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Ophthotech OPH2003 - Enrollment Closed
This a phase 2a study for fovea-sparing dry age related macular degeneration with unifocal or multifocal atrophy. It is studying intravitreal injections of a drug called Zimura by way of anti-complement C5 mechanism. This study started in January 2016 and the estimated completion date was in April 2019.
Ophthotech ZIMURA – Enrollment Closed
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD).
EyeArt – Enrollment Closed
EyeArt is an automated screening device designed automatically analyze color fundus photographs of diabetic patients to identify patients with referable or vision threatening DED. This study is designed to assess the safety and efficacy of EyeArt.
Chendgu Kanghong Biotechnology - Panda Study – Enrollment Closed
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration
Opthea DME – Enrollment Closed
A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
Senju Pharmaceutical Co MT-0814– Enrollment Closed
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration